Akums Drugs & Pharmaceuticals Ltd is a leading Indian pharmaceutical contract development and manufacturing organization (CDMO), established in 2004. Headquartered in Haridwar, Uttarakhand, the company manufactures a wide range of dosage forms—including tablets, capsules, injectables, liquid orals, eye drops, and gummies—for domestic and global clients. With EU-GMP certification for multiple facilities and a strong presence in regulated markets, Akums has emerged as a niche player in India’s pharma outsourcing ecosystem. Despite recent volatility in sales, the company reported exceptional profit growth in FY25, driven by operational efficiency and product mix optimization. This article provides a data-backed outlook on the Akums Drugs share price target 2026–2030.
Akums Drugs & Pharmaceuticals Ltd: Company Overview
- Founded: 2004
- Headquarters: Haridwar, Uttarakhand
- Key Segment: Pharmaceutical CDMO (Contract Development & Manufacturing)
- Product Portfolio: Tablets, capsules, injectables, liquid orals, eye drops, gummies
- Global Compliance: EU-GMP certified plants; supplies to regulated markets
- Ownership: Promoter-held (75.26%); not a government company
Akums is owned and controlled by its founding promoters, with no institutional backing from PSUs or foreign pharma giants. The company remains debt-free with only ₹3.93 Cr in total debt.
Akums Drugs & Pharmaceuticals Ltd: Key Financial Snapshot
| Metric | Value |
|---|---|
| Current Share Price | ₹438.00 |
| Market Capitalization | ₹6,893.86 Cr |
| No. of Shares Outstanding | 15.74 Cr |
| 52-Week High / Low | ₹623 / ₹405 |
| P/E Ratio (TTM) | 50.29 |
| P/B Ratio | 2.90 |
| EPS (TTM) | ₹8.71 |
| Book Value (TTM) | ₹150.82 |
| ROE | 13.15% |
| ROCE | 16.66% |
| Dividend Yield | 0.00% |
| Face Value | ₹2 |
| Cash | ₹356.12 Cr |
| Total Debt | ₹3.93 Cr |
| Debt-to-Equity | 0.00 |
| Sales Growth (YoY) | -9.16% |
| Profit Growth (YoY) | 197.31% |
| Promoter Holding | 75.26% |
Akums Drugs & Pharmaceuticals Ltd Share Price Target Forecast (2026–2030)
| Year | Target Price Range (₹) |
|---|---|
| 2026 | ₹470 – ₹530 |
| 2027 | ₹510 – ₹590 |
| 2028 | ₹550 – ₹660 |
| 2029 | ₹590 – ₹740 |
| 2030 | ₹630 – ₹820 |
Akums Drugs & Pharmaceuticals Ltd Share Price Target 2026
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2026 | ₹470 | ₹530 |
Akums reported a sharp 197% YoY profit surge in FY25 despite a 9.16% sales decline—highlighting improved margins and cost discipline. However, its P/E of 50.3x is significantly above the pharma sector average (~25–30x), reflecting a premium valuation. With zero debt and ₹356 Cr cash, the balance sheet is robust. A 2026 target of ₹470–₹530 assumes modest sales recovery and sustained profitability.
Akums Drugs & Pharmaceuticals Ltd Share Price Target 2027
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2027 | ₹510 | ₹590 |
The company’s EU-GMP certifications (renewed in Jan 2026) open doors to higher-value contracts in Europe and North America. If sales stabilize and R&D partnerships deepen, EPS could reach ₹9.50–₹10.50 by FY27. At a P/E of 48–52x (justified by CDMO growth potential), the 2027 range is ₹510–₹590.
Akums Drugs & Pharmaceuticals Ltd Share Price Target 2028
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2028 | ₹550 | ₹660 |
By 2028, benefits from capacity utilization and new client wins should reflect in top-line growth. The company’s asset-light model and high cash conversion support reinvestment without leverage. A P/E of 50–55x on projected EPS (~₹10–₹12) supports the ₹550–₹660 band.
Akums Drugs & Pharmaceuticals Ltd Share Price Target 2029
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2029 | ₹590 | ₹740 |
Long-term tailwinds include global pharma outsourcing and India’s “China+1” supply chain shift. Risks include client concentration and regulatory scrutiny. Using a P/E of 52–58x on FY29 EPS (~₹10.50–₹12.80), the 2029 target is ₹590–₹740.
Akums Drugs & Pharmaceuticals Share Price Target 2030
| Year | Share Price Target 1 | Share Price Target 2 |
|---|---|---|
| 2030 | ₹630 | ₹820 |
Over a five-year horizon, Akums’ value lies in its regulatory moat and export potential—not dividends (0% yield). If it sustains 15%+ ROCE and expands margins, a terminal P/E of 55–60x on FY30 EPS (~₹11–₹13.70) justifies the ₹630–₹820 range.
Akums Drugs & Pharmaceuticals Ltd: Shareholding Pattern
| Category | Holding (%) |
|---|---|
| Promoters | 75.26% |
| Domestic Institutional Investors (DII) | 14.41% |
| Foreign Institutional Investors (FII) | 1.14% |
| Public & Retail | 9.19% |
| Others | 0% |
High promoter holding ensures strategic continuity. Low FII interest suggests under-penetration—potential upside if global visibility improves.
Akums Drugs & Pharmaceuticals Ltd: Strengths vs Risks
Strengths:
- Debt-free with ₹356 Cr cash and strong operating cash flow
- EU-GMP-certified facilities enable entry into high-margin regulated markets
- Exceptional profit growth (197% YoY) despite sales headwinds
- Backed by experienced promoters with deep pharma expertise
Risks:
- Negative sales growth (-9.16%) raises sustainability concerns
- Rich valuation (P/E: 50.3x) leaves little room for execution misses
- No dividend history (0% yield) limits income appeal
- Working capital days increased from 40 to 71—signals liquidity pressure
Investment Suitability
| Factor | Assessment |
|---|---|
| Risk Profile | High |
| Ideal Time Horizon | 3–5+ years |
| Volatility | Higher than market average (small-cap pharma) |
| Dividend/Income Potential | None (0% yield) |
| Best For | Growth-oriented investors seeking niche CDMO exposure |
- Declining sales (-9.16%) despite profit growth
- Overvaluation (P/E >50x)
- Zero dividends
- Client concentration and regulatory dependency
- Rising working capital days (71 days)
Final Verdict
Akums Drugs & Pharmaceuticals is a high-quality, debt-free CDMO with strong regulatory credentials and improving profitability. However, its negative sales growth and rich valuation warrant caution. Our Akums share price target 2026–2030 (₹470 to ₹820) reflects steady appreciation—if execution stays on track and global demand holds.
Disclaimer: Price targets are estimates based on publicly available data and sector analysis. They are not investment advice. Consult a SEBI-registered advisor before making decisions.
Sources
- Screener.in – Akums Drugs Consolidated Page (FY2025 + TTM)
- Finology Ticker – AKUMS Financial Ratios & Valuation
- Akums Investor Presentation (Q3 FY26, Jan 2026)
- BSE India – Annual Report FY2025
- Company Website – EU-GMP Certification & Product Portfolio
